Pharmaceuticals(IN00372.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Pharmaceuticals
IN00372.US
News
View More

Missed out on Eli Lilly? This GLP-1 stock could be a bargain buy.

Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.

MSN·
US
IHE
-1.00%
US
XBI
-2.02%
US
LLY
-1.51%
MSN·
US
IHE
-1.00%
US
XBI
-2.02%
US
LLY
-1.51%

CITIC International expects that the release of the value of 707 drugs will drive 3SBIO upward

The research report from China Merchants Bank International indicates that the drug development program 707/PF'4404, a collaboration between Pfizer and 3SBIO, has progressed beyond expectations, with four global Phase 3 clinical studies expected to start in 2026. This drug is anticipated to become a cornerstone of the next generation of tumor immunotherapy, driving up 3SBIO's stock price. Based on increased competition, the target price has slightly decreased to 37.43 yuan, maintaining a "Buy" rating

AASTOCKS·
US
IHE
-1.00%
US
XBI
-2.02%
AASTOCKS·
US
IHE
-1.00%
US
XBI
-2.02%

Sandip Kapadia Sells 3,746 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock

CFO Sandip Kapadia of Harmony Biosciences sold 3,746 shares at $37.15 each, totaling $139,163.90, reducing his ownership by 13.25% to 24,521 shares valued at $910,955.15. This transaction was disclosed to the SEC. Recently, he also sold 20,961 shares at an average price of $35.92. The stock is currently trading at $36.84, down 2.2%. Harmony reported a quarterly EPS of $0.87, missing estimates, with revenue of $239.46 million. Analysts have set new price targets, with Mizuho raising theirs to $46.00 and maintaining an "outperform" rating.

Market Beat·
US
HRMY
-2.23%
Market Beat·
US
HRMY
-2.23%

Key facts: Sanofi faces risks if 2026 guidance misses; wins Saudi award

Bank of America analysts warn that Sanofi could face risks if its 2026 guidance misses market expectations, amid a rally in European pharma stocks and concerns over drug pricing.1Sanofi won the Nationalization Award for the Health Sector (2025) from Saudi Arabia, acknowledging its role in local talent development during the International Labor Market Conference.2

TradingView·
US
SNY
-3.62%
TradingView·
US
SNY
-3.62%

Key facts: Novo Nordisk's $500M Ad Spend Surpasses Eli Lilly; Stock Drops

In early 2025, Novo Nordisk spent nearly $500 million on U.S. ads for its GLP-1 drugs, Wegovy and Ozempic, surpassing Eli Lilly's ad budget for rival products.1Novo Nordisk (NOVO_B) fell over 2% in early European trading, amid a wider drop in European pharma stocks following the U.S. Medicare's proposed lower payment rates for 2027.2Novo Nordisk's Wegovy pill version is gaining popularity, especially among men, due to its convenience and a lower starting price of $149 per month.3

TradingView·
US
IHE
-1.00%
US
NVO
-4.07%
US
NVOX
-8.12%
TradingView·
US
IHE
-1.00%
US
NVO
-4.07%
US
NVOX
-8.12%
Posts
View More

$Novo Nordisk AS(NVO.US) is good, this longcall has doubled!

Congratulations to all bros🎉🍾, good night😴!

  • 0

$Novo Nordisk AS(NVO.US) and $Recursion Pharmaceuticals(RXRX.US) are both good, please continue😂

Tsmc will fly to the moon, let’s go!

© 2026 Longbridge｜Disclaimer